Clinical Trial Update: Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating stereotactic ablative radiotherapy (SABR) for oligometastatic metastatic cancer; currently recruiting. The study includes patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Lung Cancer
• Prostate Cancer

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Oligometastasis, Lung Cancer | Phase 3 | Status: RECRUITING